Yes / Half-sandwich metal complexes are of considerable interest in medicine, material, and nanomaterial chemistry. The design of libraries of such complexes with particular reactivity and properties is therefore a major quest. Here, we report the unique and peculiar reactivity of eight apparently 16-electron half-sandwich metal (ruthenium, osmium, rhodium, and iridium) complexes based on benzene-1,2-dithiolato and 3,6-dichlorobenzene-1,2-dithiolato chelating ligands. These electron-deficient complexes do not react with electron-donor pyridine derivatives, even with the strong σ-donor 4-dimethylaminopyridine (DMAP) ligand. The Ru, Rh, and Ir complexes accept electrons from the triphenylphosphine ligand (σ-donor, π-acceptor), whilst the Os complexes were found to be the first examples of non-electron-acceptor electron-deficient metal complexes. We rationalized these unique properties by a combination of experimental techniques and DFT/TDFT calculations. The synthetic versatility offered by this family of complexes, the low reactivity at the metal center, and the facile functionalization of the non-innocent benzene ligands is expected to allow the synthesis of libraries of pseudo electron-deficient half-sandwich complexes with unusual properties for a large range of applications.

There is an urgent need to find novel anticancer therapeutics with different mechanisms of action than platinum-containing drugs, particularly for patients who relapse after having been initially treated with a platinum-containing chemotherapy regimen. This chemoresistance phenomena, along with the serious side effects observed with cisplatin, have led research in Medicinal Inorganic Chemistry to using other precious metals for the design of novel anticancer therapeutics. This work reports on the synthesis and characterisation of a series of organometallic drug candidates based on ruthenium, osmium, rhodium, and iridium, followed by investigation of their cancer-inhibiting properties via in vitro and in vivo studies. The cytotoxicity of these complexes against various human cancer cell lines is presented, as well as preliminary studies on their possible modes of action, determined via gene expression studies, cell cycle and apoptosis analysis, reactive oxygen species detection and mitochondrial-membrane potential assays. In addition, to confirm the surprising absence of in vitro toxicity against normal cells exhibited by some compounds, studies on ex vivo/in vitro isolated human lymphocytes from healthy individuals, have been conducted. One lead molecule has been progressed to in vivo studies in mice and toxicity and efficacy were assessed with a series of assays including determination of the maximum tolerated dose and pharmacodynamic studies. Structural modifications of the lead molecule with water-soluble phosphines were subsequently undertaken, with the aim to improve the stability and solubility of the parent 16-electron specie, and evaluations of the biological activity of these novel complexes are presented.